Pharmacogenetics · 2004 · 148 citations · 21 references
MedicineMolecular GeneticsPharmacologyHepatic PharmacokineticsMolecular PharmacologyPharmacogeneticsDrug Transporter GeneticsHepatic Drug MetabolismLiver DiseaseRenal TransportersHepatic Transporter PolymorphismNon-renal ClearanceSingle-nucleotide Polymorphism AnalysisSingle-nucleotide Polymorphism VariationSingle-nucleotide PolymorphismsTransporter Gene PolymorphismsTransporter Genetic PolymorphismsTransporter Genetic Variants
OBJECTIVE: Two kinds of single nucleotide polymorphism (SNP; Asn130Asp and Val174Ala) are frequently observed in the liver specific transporter, organic anion transporting polypeptide 1B1 (OATP1B1/OATP-C) gene. Although these two SNPs occur independently in European-Americans, Val174Ala is mostly associated with Asn130Asp in Japanese. Our previous in-vivo studies in Japanese subjects indicated that the non-renal clearance of pravastatin was decreased to 13% of that in wild-type subjects (Nishizato et al. Clin Pharmacol Ther 2003;73(6):554-564). The purpose of the present study is to characterize the function of SNPs variants of OATP1B1 in cDNA transfected cells. METHODS: The localization and transport activity were analyzed in HEK293 cells stably expressing wild-type OATP1B1 (OATP1B1*1a), OATP1B1*1b (Asn130Asp), OATP1B1*5 (Val174Ala) and OATP1B1*15 (Asn130Asp and Val174Ala). To characterize the intrinsic Vmax, observed Vmax in uptake study were normalized by the expression level estimated from Western blotting. RESULTS: All SNP variants are predominantly located on the cell surface. No significant alteration was observed in Km values for the transport of 17beta-estradiol 17beta-d-glucuronide (E217betaG), a typical substrate of OATP1B1, among these SNP variants. However, the normalized Vmax value for OATP1B1*15 was drastically decreased to less than 30% compared with OATP1B1*1a. In contrast, the transport activity of OATP1B1*1b (Asn130Asp) and OATP1B1*5 (Val 174Ala) was similar to that of OATP1B1*1a. CONCLUSIONS: These results are consistent with the results of our previous clinical studies. It is thus suggested that in-vivo disposition may be predicted from in-vitro results using recombinant transporters.
21
A pharmacokinetic analysis program (multi) for microcomputer.
Kiyoshi Yamaoka, Yusuke Tanigawara, Terumichi Nakagawa et al. · Journal of Pharmacobio-Dynamics · 1981 · 2.5K citations · Full text
Sven Hoffmeyer, Oliver Burk, Oliver von Richter et al. · Proceedings of the National Academy of Sciences · 2000 · 2.4K citations
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Bonnie C. Hsiang, Yingjie Zhu, Zhaoqing Wang et al. · Journal of Biological Chemistry · 1999 · 636 citations · Full text